Cardiac Myocyte Death in the Pathogenesis of Disease
====================================================

The heart is an organ with limited capacity for regeneration and repair; hence, it is susceptible to numerous stresses and must respond to these insults in order to adapt to ever-changing workload demands. Cell death, either progressive or acute, is a hallmark characteristic of various cardiac diseases, including heart failure (HF), myocardial infarction (MI), and ischemia/reperfusion (I/R; [Figure 1](#fig1){ref-type="fig"}).^[@bib1]^ Now, at the turn of the 21st century, however, cardiovascular disease (CVD) still accounts for more than one-third of all human mortality and remains the leading cause of death worldwide. All three types of cell death, autophagic cell death, apoptosis, and necrosis, have been observed during progression of heart disease.^[@bib1]^

Autophagy
=========

One of the key cellular pathways that mediate stress-induced adaptation and damage control is macroautophagy (termed autophagy in this review). Autophagy is a highly conserved process of delivery of intracellular components, including mitochondria and long-lived macromolecules, via a double-membrane structure (autophagosome) to lysosomes for degradation.^[@bib2]^ In eukaryotic cells^[@bib2]^ and in cardiac myocytes,^[@bib3]^ starvation/nutrient deprivation, hypoxia, reactive oxygen species (ROS), damaged organelles, and protein aggregates have each been shown to induce autophagy in a mammalian target of rapamycin (mTOR)-dependent process. Similarly, mTOR-independent autophagy has been reported; cytokines, which do not exist in yeast, converge on type III phosphatidylinositol 3-kinase to induce autophagy.^[@bib4]^

Autophagy in Response to Ischemia and I/R
=========================================

More than 95% of the energy required for cardiac myocyte function is derived from oxidative phosphorylation. Interruption of blood flow to the myocardium disrupts oxygen supply, triggering rapid declines in ATP and increased AMP/ATP ratios. Autophagy, as a pro-survival mechanism that replenishes energy under stress conditions, is activated. Ischemia/hypoxia induces autophagy *in vivo* and *in vitro* in most,^[@bib5],\ [@bib6]^ although not all,^[@bib7]^ studies. The two pathways responsible for ischemia/hypoxia-induced autophagy involve either BNIP3^[@bib8]^ or AMPK.^[@bib9]^ In a mouse model expressing dominant-negative AMPK in cardiac myocytes, the autophagic response to ischemia was attenuated, leading to larger MI and worse cardiac function.^[@bib9]^ If ischemia is prolonged, the autophagic response becomes dysfunctional, as evidenced by the existence of impaired autolysosomes.

During reperfusion, autophagy is upregulated further, even though the delivery of oxygen and nutrients is restored and AMPK is rapidly inactivated.^[@bib5],\ [@bib10]^ The continued activation of autophagy during reperfusion is qualitatively different than that in ischemia, especially in terms of mechanisms of induction. Stimulators, such as oxidative stress, mitochondrial damage/BNIP3, endoplasmic reticulum stress, and calcium overload, likely have more important roles in maintaining autophagy at a higher level during reperfusion.^[@bib11]^ Although the available evidence is consistent that autophagy is protective under conditions of mild-to-moderate ischemia, the same cannot be said of autophagy elicited by reperfusion. Indeed, upregulation of autophagy can be either beneficial or detrimental in the context of I/R.^[@bib5],\ [@bib10]^

Recent evidence reveals that autophagosome clearance is impaired in I/R. Ischemia induces a decline in the levels of LAMP2, a protein critical for autophagosome--lysosome fusion, mediated by ROS-induced activation of serine and cysteine proteases; reperfusion induces upregulation of Beclin 1, which further impairs autophagosome processing, culminating in increased ROS generation, mitochondrial permeabilization, and cardiomyocyte death.^[@bib12]^ More investigation is needed to clarify when and how elevated autophagy may be pro-survival to cardiac myocytes subjected to reperfusion injury.

Autophagy in Response to MI
===========================

There is limited information regarding autophagy in the context of MI. The most likely region where autophagy might be important is the sublethally injured, peri-infarct zone. In addition, autophagy may contribute to the more global process of postinfarction remodeling. Activation of AMPK by metformin blunted development of HF induced by MI, and inhibiting mTOR led to reduced remodeling and improved cardiac function after MI.^[@bib13]^ Moreover, STAT1 deficiency is protective by enhancing autophagy in an *ex vivo* model of MI.^[@bib14]^ However, the possible role of autophagic flux in the heart was not examined in these studies. Although these data suggest that agents known to regulate pathways that augment autophagy were protective, direct evidence is lacking regarding the specific role that autophagy has in MI.

Autophagy in Response to Cardiac Hypertrophy and HF
===================================================

In response to hemodynamic stress, such as pressure overload, the heart hypertrophies. Cardiac hypertrophy (CH) is thought to be an adaptive process initially; however, it becomes detrimental to cardiac function if left unchecked. CH is a major, independent risk factor for systolic dysfunction and clinical HF.^[@bib15]^ In HF patients, cardiac myocyte death with autophagic features occurred at a rate of 0.03% in human-dilated cardiomyopathy (C), as compared with 0.002% for apoptotic cell death.^[@bib16]^ Together, these lines of evidence support the notion that autophagy participates in the pathogenesis of HF. The specific role of autophagy, however, in the pathogenesis of CH and HF-related remodeling is less clear.

The strongest evidence that autophagy facilitates development of pathological hypertrophy derives from genetic manipulations of the core autophagic machinery in mouse models.^[@bib17],\ [@bib18]^ In contrast, several lines of evidence highlight the fact that autophagy can have an anti-hypertrophic role. The latter notion, however, requires additional corroboration, as it relies largely on indirect pharmaceutical manipulations of autophagy via upstream pathways.^[@bib19],\ [@bib20],\ [@bib21]^ Here, we will briefly detail the studies supporting both concepts (see [Figure 2](#fig2){ref-type="fig"} for an overview of major regulators of autophagy targeted in these studies).

CH was attenuated in *Beclin 1* haploinsufficient hearts. Overexpression of Beclin 1 led to exacerbated hypertrophic growth in response to pressure overload.^[@bib18]^ Importantly, a recent study by our group suggested that autophagy is necessary for the process of CH. In this study, moderate pressure overload that induces CH also activated autophagy, and blocking this process inhibited pathological heart remodeling. RNAi-dependent knockdown of ATG5 and Beclin 1 attenuated the growth response induced by hypertrophic agonists.^[@bib17]^

Conversely, inhibition of mTOR, an upstream repressor of autophagy, blunts CH, both clinically and in an animal model.^[@bib20],\ [@bib22]^ However, the status of autophagy in these patients and animal hearts was not tested following treatment with rapamycin.^[@bib20],\ [@bib22]^ Inactivation of cardiac mTOR was also associated with marked elevation of apoptosis and declines in myocardial function and accelerated progression to HF.^[@bib21]^ This could be rescued by deletion of a direct target of mTOR, 4E-BP1, although without notable changes in autophagy, suggesting that this process may not be a major contributor to the development of HF in these animals; rather, inhibition of protein synthesis may be the primary mechanism. In accordance, cardiomyocyte-specific inactivation of Raptor, a component of the mTOR complex 1, induces dilated C and high mortality within 6 weeks, with increases in apoptosis and autophagy. This evidence demonstrates a specific role of mTOR in preserving cardiac function.^[@bib19]^

An emerging concept of an optimal, 'adaptive zone\' of autophagic activation suggests an explanation of all this seemingly conflicting evidence. According to this concept, too much or too little autophagy may lead to increased hypertrophy and heart dysfunction. Supporting this, the conditional loss of function of *Atg5* in adult mice led to rapid progression to hypertrophy and cardiac dysfunction in the absence of pressure overload.^[@bib23]^

It may seem counterintuitive that blocking a catabolic pathway inhibits cardiac growth. However, cardiac myocytes are not quiescent structures; their components, including sarcomeres and mitochondria, are highly dynamic and constantly turning over. Indeed, the phenomenon of activation of both anabolic and catabolic processes during development of CH was observed long ago. However, the specific role of autophagy as a part of the catabolic process in CH has only recently started to surface. One day, it may emerge as a target for CH and HF therapy.

Translational Implications in Cardiac Autophagy
===============================================

Modulation of the autophagic pathway may represent a future therapeutic target in heart disease. However, the complex nature of autophagic mechanisms and the lack of autophagy-specific inducing and blocking agents all contribute to limiting its therapeutic application. Agents such as metformin and rapamycin, an AMPK activator and mTOR inhibitor, respectively, have been tested in clinical settings for purposes other than autophagy. Metformin is used commonly in patients with diabetes, and its use diminishes all-cause mortality and MI.^[@bib24]^ More recently, animal models of ischemia and I/R have reported beneficial effects of metformin by decreasing infarct size and blunting HF.^[@bib25]^ Other medications used in MI, such as *β-*blockers (e.g., propranolol) and calcium channel blockers (e.g., verapamil), were examined more than 20 years ago.^[@bib26],\ [@bib27]^ These studies found that the *β*-adrenergic agonist isoproterenol inhibited autophagy;^[@bib27]^ and propranolol and verapamil had the opposite effect.^[@bib26]^ These actions, however, were rather short lived, lasting only 10 min.^[@bib26],\ [@bib27]^ The long-term impact on autophagy of *β-*blockers and calcium channel antagonists are unknown and potentially clinically relevant, as patients typically use them chronically to control blood pressure and symptoms from ischemic heart disease. On the other hand, the *α*1-adrenergic receptor agonist phenylephrine increases cardiac myocyte autophagy.^[@bib17]^

Autophagy can be activated by caloric restriction.^[@bib28]^ In animal models, caloric restriction attenuates age-related changes in the heart, including hypertrophy, myocardial fibrosis, shifts in myosin isoform composition, histological changes, apoptosis, and the deterioration of chronotropic and inotropic responses to adrenergic stimulation.^[@bib28]^ In humans, echocardiographic studies have shown that caloric restriction improves diastolic function in healthy nonobese humans in conjunction with reductions in indices of myocardial stiffness.^[@bib28]^ It is apparent that more research is needed before any conclusion can be drawn regarding the exact role autophagy has in ischemia and I/R, so that agents specifically designed as autophagy inducers or inhibitors can be considered clinically.

Recent work has provided insight into how autophagy contributes to CH. Evidence supports the notion that activation of autophagy is required for both myocyte growth and to maintain homeostasis in an enlarged, hypertrophied myocyte. Histone deacetylase (HDAC) inhibitors suppress the maladaptive autophagic response, contributing to their anti-hypertrophic effects and leading to improved cardiac function.^[@bib17]^ Indeed, increased autophagic activity may be a universal feature of C, including chemotherapy-induced C and HF. The clinical relevance of HDAC inhibitors and autophagy in the heart is potentially significant, as these agents are currently used in patients as cancer chemotherapy. Conceivably, they are in a unique position to kill cancer cells and protect the heart at the same time.

In summary, the role of autophagy is intricate, and its contribution to heart disease is complex. Many aspects are still debated and actively investigated. However, maintenance of a balance of autophagy is critical, not too much and not too little ([Figure 3](#fig3){ref-type="fig"}).

Apoptosis
=========

Apoptosis is mediated by two pathways, the extrinsic and the intrinsic pathways, and both have been described in cardiac myocytes.^[@bib1]^ The extrinsic apoptotic pathway can be triggered by FAS ligand, tumor necrosis factor (TNF)-*α*, or TRAIL. Both FAS and TNF receptor I are expressed in cardiac myocytes and have been implicated in cardiovascular pathology.^[@bib1]^ TRAIL has also been reported to be released by cardiac myocytes,^[@bib29]^ but no further information is available about TRAIL and the heart. Cardiac myocyte-specific overexpression of TNF-*α* in transgenic mice provoked dilated C and HF,^[@bib30]^ suggesting that activation of the death receptor pathway by TNF-*α* is harmful to the heart ([Figure 4](#fig4){ref-type="fig"}).

The mitochondrion is the primary organelle involved in mediating the intrinsic apoptotic pathway. In cardiac myocytes, mitochondria are located at intermyofibrillar spaces and underneath the sarcolemma. This strategic distribution of mitochondria allows for efficient ATP supply to the high-energy demand, continuously contracting cardiac myocyte. However, because mitochondria can also contribute to cell death in response to multiple stresses, cardiac myocytes have developed special strategies to achieve strict control over the intrinsic apoptotic pathway.^[@bib1],\ [@bib31]^ Cardiac myocytes express various members of the BCL2 family, several of which are transcriptionally regulated in heart disease, including anti-apoptotic and pro-apoptotic BCL2 proteins.^[@bib32]^

Cardiac myocytes express low levels of Apaf1, and a consequence of this low Apaf1 activity is the engagement of strict control of caspase (casp) activation by endogenous XIAP.^[@bib33]^ In fact, direct microinjection of cytochrome *c* (cyto *c*) into cardiac myocytes was not sufficient to induce apoptosis.^[@bib33]^ This observation is consistent with studies showing substantial translocation of cyto *c* into the cytosol, without much detectable apoptosis in human cardiomyopathic hearts.^[@bib34]^ Downregulation of XIAP and cIAP1/2 in cardiac myocytes within the failing myocardium has been suggested to contribute to increased cardiac myocyte apoptosis.^[@bib34]^ Transgenic mice overexpressing cIAP2 had reduced infarct size and fewer TUNEL-positive cells after I/R.^[@bib35]^ IAPs can also be inhibited by SMAC/DIABLO and OMI/HTRA2, and inhibition of OMI/HTRA2 reduced apoptosis and infarct size in rat after I/R.^[@bib36]^

Mitochondria in Cardiac Myocyte Apoptosis
=========================================

It has been suggested that activation of the mitochondrial apoptotic pathway leading to executioner casp activation is relevant in heart injury.^[@bib1]^ The notion of participation of casp activation in adult cardiac myocyte apoptosis emerged from studies using immunofluorescence microscopy^[@bib16]^ and casp inhibitors.^[@bib37]^ Bahi *et al.*^[@bib38]^ demonstrated that cardiomyocyte levels of all casps decrease with age, and they are very low in adult cardiac cells. Recently, Bae *et al.*^[@bib39]^ reported that apoptosis can be induced in the heart lacking casp activation via casp-independent pathways, probably through apoptosis-inducing factor (AIF). Both the intrinsic and extrinsic pathways can be inhibited by the cytoprotective protein apoptosis repressor with caspase recruitment domain (ARC). ARC inhibits the extrinsic pathway by interacting with casp 8 and components of the death-inducing signaling complex, such as FADD, whereas inhibition of the intrinsic pathway is mediated by blocking BAX activation and mitochondria translocation.^[@bib40]^

AIF is anchored by its N terminus to the mitochondrial inner membrane, with its C terminus oriented toward the intermembrane space. AIF is required for oxidative phosphorylation and for the assembly and/or stabilization of respiratory complex I.^[@bib41]^ Upon induction of apoptosis, AIF is cleaved and released into the cytosol, where it translocates to the nucleus and mediates chromatin condensation and large-scale DNA fragmentation.^[@bib41]^ However, this well-known pro-apoptotic action of AIF is in conflict with the observation that AIF is essential for the maintenance of normal heart function and its inactivation results in dilated C.^[@bib42]^ Moreover, cardiac myocytes isolated from a mouse model with 80% reduction in AIF levels manifested increased cell death induced by oxidative stress, and the hearts of these mice displayed enhanced ischemic damage after *in vivo* I/R.^[@bib43]^ Although it has been described that AIF is released from cardiac myocyte mitochondria during I/R, its contribution to I/R-induced apoptosis was discounted.^[@bib38]^ However, AIF has been implicated in cardiac myocyte death induced by oxidative stress and HF.^[@bib44]^

Endonuclease G (Endo G) is a nuclear-encoded endonuclease localized to the intermembrane space of mitochondria. In cardiac myocyte apoptosis, Endo G translocates to the nucleus, where it cleaves DNA. In heart and cultured cardiac myocytes, Endo G has a role in I/R-mediated cell death.^[@bib38]^ Activation of the intrinsic pathway by the extrinsic apoptotic pathway can take place through casp-8-dependent cleavage of BCL2-interacting protein (BID) to truncated BID (t-BID). The C-terminal fragment of t-BID subsequently translocates to the mitochondrial outer membrane, where it presumably activates the intrinsic pathway. This pathway is operative in the heart.^[@bib1]^

Mitochondrial Dynamics and Apoptosis
====================================

Mitochondria exist as a complex, interconnected, and highly dynamic network characterized by the ongoing and counterbalanced events of mitochondrial fusion and fission.^[@bib45]^ Mitochondrial fission is regulated by DRP-1 and FIS1, whereas mitochondrial fusion is controlled by mitofusins 1/2 (MFN1/2) and OPA1.^[@bib45]^ Changes in the mitochondrial morphology of cardiac myocytes have been reported in several heart diseases.^[@bib46]^ Fragmentation of the mitochondrial network in response to apoptotic stimuli is a frequent finding observed in cardiac myocytes.^[@bib47]^ Loss of integrity of the mitochondrial membrane is mediated by a complex process that involves DRP-1, MFN2, and the pro-apoptotic protein BAX.^[@bib45],\ [@bib46]^ Decreases in the abundance of MFN2 is associated with an increase in mitochondrial fragmentation and cyto *c* release, pointing to a protective role of MFN2 against apoptotic death.^[@bib47]^

Recently, emerging evidence suggests that the unfolded protein response (UPR) has important roles in pressure overload-triggered HF.^[@bib48]^ UPR markers, including GRP78, calreticulin and GRP94, are significantly upregulated in mouse heart in the setting of pressure overload.^[@bib48]^ Angiotensin II administration can induce ER stress and apoptosis in cultured cardiomyocytes. Furthermore, CHOP activation in pressure overload contributes to CH and HF.^[@bib49]^ Fu *et al.*^[@bib49]^ showed that CHOP-deficient animals manifested less CH, fibrosis, and cardiac dysfunction in the setting of pressure overload. These studies highlight the critical role of ER stress in CH and HF.

Apoptosis in HF
===============

Apoptosis is rare in normal human myocardium, with a reported prevalence of approximately one TUNEL-positive cardiac myocyte per 10 000--100 000, that is, 0.01--0.001%. In human failing hearts of New York Heart Association class III--IV, apoptotic cells are detectable in the range of 0.12--0.70%.^[@bib50]^ In all reported cases, apoptosis levels were substantially lower than 1%. Because the limited ability of cardiac myocytes to proliferate, low levels of apoptosis can still have profound effects. Mani^[@bib51]^ has postulated that an apoptotic rate of 0.1% would be expected to result in a ∼37% loss in cardiac myocyte number over a year. This issue was addressed by generating transgenic mice with cardiac myocyte-specific expression of an inducible casp 8.^[@bib52]^ These transgenic mice developed severe, dilated C over 8 weeks and died within 2--6 months, manifesting disease progression that was markedly accelerated as compared with healthy wild-type mice that exhibited apoptotic rates of ∼0.002%.^[@bib52]^ This finding suggests that a very low, albeit elevated, rate of apoptosis can be an important component of HF pathogenesis.

Apoptosis in MI and I/R
=======================

Because of the intrinsically low levels of Apaf1 and casps in cardiac myocytes, nonmyocyte cells within the heart may be more susceptible to apoptosis. This, in turns, complicates the study of cardiac myocyte apoptosis in whole heart. Permanent coronary occlusion induced maximum cardiac myocyte apoptosis at 4.5 h, whereas necrosis peaked at 24 h.^[@bib53]^ Reperfusion appeared to accelerate the timing of apoptosis as compared with permanent occlusion.^[@bib54]^

Mice that lack FAS (*lpr* mice) exhibited a decrease in cardiac myocyte apoptosis in models of doxorubicin toxicity,^[@bib55]^ as well as marked reductions in infarct size following I/R.^[@bib56]^ However, deletion of either TNFR1 or TNFR2 does not affect infarct size. In contrast, deletion of both together resulted in significantly larger infarcts following permanent coronary occlusion.^[@bib57]^ These results suggest that FAS, and not TNFR, is the major mechanism for activating the extrinsic apoptotic pathway during MI.

Cardiac myocyte-specific overexpression of BCL2 substantially reduces infarct size, cardiac myocyte apoptosis, and cardiac dysfunction following I/R.^[@bib58]^ BAX deficiency reduces infarct size and cardiac dysfunction following I/R and following MI in mice.^[@bib59]^ Targeted deletion of PUMA reduced infarct size ∼50% in an *ex vivo* Langendorff I/R model.^[@bib60]^ Together, these results suggest that the intrinsic apoptosis pathway also has a central role in MI.

Translational Implications of Cardiac Apoptosis
===============================================

To date, no clinical trial has been attempted to specifically block or inhibit apoptotic pathways during MI. However, in chronic HF, clinical trials have been carried out using compounds that deplete circulating TNF-*α*.^[@bib61]^ Etanercept is a recombinant human-soluble TNF receptor that binds to and neutralizes circulating TNF-*α*.^[@bib61]^ Despite encouraging results in small pilot trials,^[@bib61],\ [@bib62]^ large multicenter trials of etanercept in moderate-to-severe HF did not demonstrate significant clinical benefit and even suggested that etanercept may adversely affect the course of the disease.^[@bib61],\ [@bib63]^

Infliximab is a recombinant human-murine chimeric monoclonal antibody that specifically binds to and neutralizes TNF-*α*.^[@bib64]^ Infliximab improved left ventricular function and limited HF in TNF-*α* overexpressing transgenic mice.^[@bib64]^ However, the ATTACH trial did not detect HF improvement, but rather uncovered a signal for adverse events in patients with moderate to severe HF.^[@bib61],\ [@bib65]^ These disappointing results might be explained by the dual action of TNF-*α*: short-term beneficial but long-term harmful effects. More encouraging results have been obtained with pentoxifylline, a xanthine-derived compound that directly modulates TNF-*α* mRNA expression,^[@bib66]^ (as opposed to neutralizing circulating TNF-*α*). A single-center, placebo-controlled trial of pentoxifylline reported improvement in left ventricular performance in idiopathic dilated C.^[@bib67]^ A large multicenter trial is warranted.

Necrosis
========

Necrosis is marked by distinct morphological changes, including cell swelling, plasma membrane damage, loss of ATP, and organelle swelling. Disruption of cell integrity and release of cellular contents trigger a secondary inflammatory response, with potential pathological consequences.^[@bib1]^ Necrosis is mainly caused by physical or chemical trauma to the cell and has long been considered as passive and accidental cell death.^[@bib68]^ Recently, however, emerging evidence suggests that a proportion of necrosis is regulated by serial signaling events in a controlled and orchestrated manner. Several terms have been introduced to describe this form of necrosis, such as programmed necrosis, casp-independent cell death, and necroptosis.^[@bib69]^ A number of mechanisms has been proposed to explain the initiation and execution of necrosis, including death receptors, ROS, Ca^2+^, and mitochondrial permeability transition pore (MPTP) opening ([Figure 5](#fig5){ref-type="fig"}).^[@bib68],\ [@bib70]^

Necrosis in HF
==============

A characteristic feature of HF is progressive dropout of cardiac myocytes and development of cardiac dysfunction. As noted above, early studies suggested that apoptosis serves as one critical factor contributing to cell demise in end-stage HF. However, later observations suggested that necrosis is more prominent in failing human heart, contributing several fold more to disease pathogenesis than apoptosis in both men and women.^[@bib71]^ Mechanistically, sustained Ca^2+^ stress, together with persistent activation of adrenergic receptors, triggers necrotic cell death. Using inducible overexpression of the L-type Ca^2+^ channel (LTCC) specifically in cardiac myocytes, Nakayama *et al.*^[@bib72]^ found that an increase of LTCC activity promoted progressive cell death, and coadministration of an adrenergic receptor agonist amplified this process. Importantly, cardiac myocytes were protected from cell death when cyclophilin D is absent, suggesting the MPTP and necrosis are involved.^[@bib73],\ [@bib74]^ In contrast, forced expression of the anti-apoptotic protein BCL2 did not rescue cell death by Ca^2+^ overloading. These data suggest strongly that necrosis contributes to the progression of HF, and that Ca^2+^ handling and MPTP opening may be critically involved.

Necrosis in MI
==============

During MI, activation of anaerobic glycolysis to provide ATP leads to accumulation of H^+^ and acidosis. Ion pumps on the plasma membrane respond to remove excess H^+^ in exchange of Na^+^. In response to elevated levels of intracellular Na^+^, the Na^+^/Ca^2+^ exchanger operating in reverse mode is less capable of removing intracellular Ca^2+^, culminating in increased cytoplasmic Ca^2+^ levels. The mitochondrial Ca^2+^ uniporter then transports Ca^2+^ into mitochondria. Increases in Ca^2+^ within this organelle induces Ca^2+^-dependent dehydrogenase activation, declines in NADH and electron flux through the electron transport chain, increased ROS, and decreases in ATP levels. As Ca^2+^ uptake into mitochondria dissipates mitochondrial membrane potential, eventually the increase in matrix Ca^2+^ reaches a plateau under hypoxic conditions due to limitation of the proton gradient. Upon reperfusion, however, restoration of oxygen and ATP-generating capabilities quickly recovers ATP levels and mitochondrial membrane potential. These changes regenerate the required ion gradient for more Ca^2+^ entry into mitochondria, which causes long-lasting opening of MPTP regulated by cyclophilin D, and mitochondrial swelling leads ultimately to cellular necrosis.^[@bib1]^

Some evidence implicates MPTP opening as a mechanistic link between myocyte necrosis and I/R injury. Involvement of MPTP in cardiac I/R responses was elegantly illustrated by the Molkentin and Tsujimoto groups.^[@bib73],\ [@bib74]^ Using similar genetic approaches, they found that lack of cyclophilin D protected cardiac myocytes from Ca^2+^ overload-induced cell death *in vitro*. Infarct size and lactate release from the heart were dramatically reduced in the mutant animals after I/R. Interestingly, pro-apoptotic protein-induced cyto *c* release did not differ between wild-type and knockout mitochondria, suggesting that cyclophilin D does not have a critical role in apoptosis.

Translational Implications of Necrosis
======================================

Promising work on MPTP opening from *in vitro* tissue culture and *in vivo* animal studies has provided hints regarding therapeutic targets to protect the heart from necrosis. Cyclosporin is a potent inhibitor of MPTP. A pilot clinical trial by Piot *et al.*^[@bib75]^ found that acute treatment with cyclosporin upon reperfusion at the time of percutaneous coronary intervention was associated with reduced infarct size and reduced creatine kinase and troponin I release. Although these results are encouraging and suggest that inhibition of MPTP is key in the protection against necrotic death during I/R, additional experimental work is needed to determine the contribution of other targets of cyclosporin, such as calcineurin or nitric oxide synthase (NOS), in this cardioprotection.

Necrostatin-1 is a selective inhibitor of necroptosis, a specialized pathway of programmed necrosis, targeting the kinase RIP1.^[@bib76]^ *In vitro* studies using cancer cell lines reported protective effects of necrostatin-1 in TNF-*α* induced necrosis. More recently, the role of necrostatin-1 in cardiac I/R has been evaluated.^[@bib76]^ A bolus dose of necrostatin-1 in wild-type mice at the time of coronary reperfusion dramatically reduced infarct size after I/R injury, whereas no protection was found in cyclophilin D-deficient animals. Necrostatin-1 may hold promise for consideration of clinical use.

Stem Cell Therapy for HF
========================

MI and HF are associated with significant loss of cardiac myocytes, a process that has been thought to be irreversible. However, the discovery of tissue resident cardiac stem cells and the ability of exogenously delivered bone marrow (BM)-derived stem cells to confer benefit have recently challenged this long held belief.^[@bib77]^ These discoveries have stimulated basic and clinical research, with the aim of employing the regenerative properties of stem cells to repair damaged myocardium, improve cardiac function, and improve patient morbidity and mortality.^[@bib77]^

Skeletal muscle cells have been considered as an alternative cell source for transplantation to improve cardiac function in animal models, which indeed succeeded. However, subsequent clinical trials revealed a significant signal for arrhythmic harm.^[@bib78]^ Other types of cells, such as cultured cardiac stem cells, embryonic stem cells, or induced pluripotent stem cells, have also been considered as cellular sources for generating cardiac myocytes.^[@bib79]^ Early reports showing that BM-derived adult stem/progenitor cells manifest greater plasticity than expected and can differentiate into cardiac myocytes raised the hope that BM-derived stem cells may improve both neovascularization and repair of the infarcted heart. Although there have been several basic research and numerous clinical studies showing that different subpopulations of BM-derived stem cells and other progenitor cells are capable of enhancing heart function, the signaling pathways involved and the extent to which progenitor cells are able to reestablish cardiac function in stage IV HF is extensively debated.^[@bib77],\ [@bib79]^

Conclusions and Perspectives
============================

Autophagy, apoptosis, and necrosis are major mechanisms in the pathogenesis of CVD. A summary of interventions showing the relevance of autophagy, apoptosis, and necrosis in cardiac myocyte cell death and/or heart diseases is depicted in [Table 1](#tbl1){ref-type="table"}. One day, clinical therapy targeting myocyte cell death is envisioned. Even though some translational applications have been tested already, manipulation of cardiac myocyte death is in its infancy. Currently, 55 patent applications related to the control of cardiac myocyte death/survival (5 in necrosis, 29 in apoptosis, 11 in apoptosis and/or necrosis, and 10 in autophagy) and its application to treatment of CVDs have been filed ([Table 2](#tbl2){ref-type="table"}). However, none of these products has emerged with success in clinical trials. Major translational challenges remain in this exciting area, but patients with heart disease are likely to benefit from these efforts.

We thank the members from the Hill lab and Lavandero lab for helpful discussions. This work was supported by grants from the NIH (HL-075173, JAH; HL-080144, JAH; and HL-090842, JAH), AHA (0640084N, JAH), the AHA-Jon Holden DeHaan Foundation (0970518N, JAH), and the Fondo Nacional de Desarrollo Cientifico y Tecnologico: FONDECYT 1080436 and FONDAP 15010006 (SL). ZVW, ZP, and RT are supported by postdoctoral fellowships from the American Heart Association 10POST4320009 and FONDECYT 3110039 and 3110114, respectively.

AIF

:   apoptosis-inducing factor

ARC

:   apoptosis repressor with caspase recruitment domain

ATH

:   atherosclerosis

BID

:   BCL2-interacting protein

BM

:   bone marrow

C

:   cardiomyopathy

casp

:   caspase

CHF

:   congestive heart failure

CVD

:   cardiovascular disease

cyto *c*

:   cytochrome *c*

Endo G

:   endonuclease G

F

:   myocardial fibrosis

CH

:   cardiac hypertrophy

HDAC

:   histone deacetylase

HF

:   heart failure

HT

:   hypertension

LVR

:   left ventricular remodeling

MI

:   myocardial infarction

MIS

:   myocardial ischemia

I/R

:   ischemia/reperfusion

LTCC

:   L-type Ca^2+^ channel

MFN1/2

:   mitofusins 1/2

MPTP

:   mitochondrial permeability transition pore

mTOR

:   mammalian target of rapamycin

RI

:   reperfusion injury

TNF

:   tumor necrosis factor

ROS

:   reactive oxygen species

t-BID

:   truncated BID

UPR

:   unfolded protein response

Edited by RA Knight

The authors declare no conflict of interest.

![Aging, stress, and cell death progression. The cell injury marker troponin T increased during aging, as well as with different CVDs (de Lemos *et al.*)[@bib81]](cddis2011130f1){#fig1}

![Schematic overview of the regulators of autophagy described in this section: Atg5 and Beclin 1 -- components of the core autophagic machinery; mTOR and Raptor are components of the mTOR complex 1, an upstream repressor of autophagy; rapamycin -- an inhibitor of mTOR (activates autophagy by releasing mTOR-mediated inhibition)](cddis2011130f2){#fig2}

![The Goldilocks rule of autophagy in heart disease. Autophagy is a dynamic process. The relationship between autophagy and heart disease is complex. Although basal autophagy is critical to maintain cellular and whole-body homeostasis, both increases and decreases in autophagy to excessive degree can be maladaptive. In CH, HF, and I/R, autophagic flux is abnormally elevated, contributing to cardiac dysfunction. With aging, Pompe disease, and Danon disease, autophagic activity and processing are attenuated, perturbing cellular homeostasis and contributing to cardiac disease. Animal models have been studied extensively to evaluate the role of autophagy in heart disease with either increases (Beclin 1 tg) or decreases (Atg5 KO, Beclin 1 het) in autophagic activity](cddis2011130f3){#fig3}

![Apoptotic pathway in cardiac myocytes. In the extrinsic pathway, death receptor activation by a death ligand induces death-inducing signaling complex (DISC) formation and casp 8 activation, which in turn activates casp 3. This pathway can also activate the intrinsic pathway by the proteolysis of BID to t-BID by casp 8 and interaction of t-BID with BAX in the mitochondria. Pro-apoptotic BAX/BAK induces cyto *c*, Smac/DIABLO, AIF, and Endo G release from the mitochondria. Cyto *c* with Apaf1 and casp 9 form the apoptosome with activation of casp 9. Casp activity is regulated by the endogenous casp inhibitor XIAP. Cardiac myocytes are naturally resistant to apoptosis due to their low-level expression of Apaf1 and casps and high levels of XIAP](cddis2011130f4){#fig4}

![Necrosis pathways in cardiac myocytes. During certain cardiac pathologies, such as I/R, the action of cellular pumps is inhibited by ATP depletion, there is a consequent increase in H^+^ and Na^+^, and the sodium-calcium exchanger (NCX) operates in reverse manner. Increased cytoplasmic Ca^2+^ leads to increased Ca^2+^ in the mitochondrial matrix along with elevated levels of ROS, culminating in MPTP opening, and necrosis. On the other hand, mitochondrial swelling and mitochondrial membrane rupture also produce necrosis. Moreover, increased H^+^ in the cytoplasm and inactivation of H^+^ pumps elicit declines in lysosomal pH, which results in overactivation of proteases such as cathepsins. The massive entry of water results in lysosomal swelling, membrane rupture, and release of proteases into the cytoplasm, which together with other activated proteases, such as calpains, digest different substrates, including cytoskeletal proteins, contributing to necrosis. Activation of death receptors, such as the TNF-*α* receptor, represents other necrosis pathways in cardiac myocytes under certain conditions such as HF. The activation of these receptors could lead to the activation of receptor-interacting protein (RIP), increased ROS, and necrosis. The massive inflow of water into the cell by the osmotic imbalance ultimately leads to cell swelling and rupture of the plasma membrane](cddis2011130f5){#fig5}

###### Autophagy, apoptosis, and necrosis interventions

  **Type**    **Intervention**                                                                                 **Model**                     **Effect**                                                                                                                                              **Reference**
  ----------- ------------------------------------------------------------------------------------------------ ----------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  Autophagy   Dominant-negative AMPK                                                                           Transgenic mouse              Attenuated autophagic response to ischemia with larger MI and worse cardiac function                                                                    Russell *et al.*^[@bib9]^
              Activation of AMPK with metformin                                                                Rat                           Reduction of HF induced by MI                                                                                                                           Buss *et al.*^[@bib13]^; Yin *et al.*^[@bib25]^
              STAT1 deficiency                                                                                 Transgenic mouse              Enhanced autophagy that protects upon reperfusion                                                                                                       McCormick *et al.*^[@bib14]^
              *Atg5* knockout                                                                                  Transgenic mouse              Rapid progression to hypertrophy and cardiac dysfunction with pressure overload                                                                         Nakai *et al.*^[@bib23]^
              Beclin 1 heterozygous disruption                                                                 Transgenic mouse              Decreased heart hypertrophy to pressure overload                                                                                                        Zhu *et al.*^[@bib18]^
              Beclin 1 overexpression                                                                          Transgenic mouse              Exacerbated heart hypertrophy to pressure overload                                                                                                      Zhu *et al.*^[@bib18]^
              Propranolol (*β*-blocker) and verapamil (calcium channel blocker)                                Rat                           Induction of autophagy                                                                                                                                  Bahro and Pfeifer^[@bib26]^
              Isoproterenol (*β*-adrenergic agonist)                                                           Rat                           Inhibition of autophagy                                                                                                                                 Pfeifer *et al.*^[@bib27]^
              Phenylephrine (*α*1-adrenergic agonist)                                                          Cultured rat cardiomyocytes   Induction of autophagy                                                                                                                                  Cao *et al.*^[@bib17]^
              Histone deacetylase                                                                              Cultured rat cardiomyocytes   Suppression of maladaptive autophagic response                                                                                                          Cao *et al.*^[@bib17]^
                                                                                                                                                                                                                                                                                                      
  Apoptosis   Overexpression of cIAP2                                                                          Transgenic mouse              Reduced infarct size and TUNEL-positive cells after I/R                                                                                                 Chua *et al.*^[@bib35]^
              Inhibition of OMI/HTRA2                                                                          Rat                           Reduction of apoptosis and infarct size after I/R                                                                                                       Bhuiyan and Fukunaga^[@bib36]^
              Caspase inhibition with YVAD-cmk                                                                 Rat                           Reduced infarct size and TUNEL-positive cells after I/R                                                                                                 Holly *et al.*^[@bib37]^
              Doxorubicin treatment of caspase inhibitor CrmA in overexpressing mice                           Transgenic mouse              Induction of apoptosis in hearts lacking caspase activation via caspase-independent pathways, probably by AIF                                           Bae *et al.*^[@bib39]^
              Cardiac-specific expression of inducible caspase 8                                               Transgenic mouse              Presence of 0.023% of apoptosis, with development of severe dilated cardiomyopathy over 8 weeks and death after 2--6 months                             Wencker *et al.*^[@bib52]^
              FAS knockout                                                                                     Transgenic mouse              Decreased apoptosis upon doxorubicin treatment and reduction of infarct size following I/R                                                              Nakamura *et al.*^[@bib55]^; Lee *et al.*^[@bib56]^
              Cardiac-specific overexpression of BCL2                                                          Transgenic mouse              Reduction of infarct size, apoptosis and cardiac dysfunction after I/R                                                                                  Chen *et al.*^[@bib58]^
              BAX knockout                                                                                     Transgenic mouse              Reduction of infarct size and cardiac dysfunction following I/R and MI                                                                                  Hochhauser *et al.*^[@bib80]^
              PUMA knockout                                                                                    Transgenic mouse              Reduction of infarct size in an *ex vivo* Langendorff I/R model                                                                                         Toth *et al.*^[@bib60]^
              Etanercept, a recombinant human-soluble TNF receptor                                             Clinical trials               Nonsignificant clinical benefits                                                                                                                        Balakumar and Singh^[@bib61]^; Mann *et al.*^[@bib63]^
              Infliximab, a recombinant chimeric TNF-*α*-neutralizing monoclonal antibody                      Clinical trials               Non-HF improvement and increased adverse effects in patients with moderate-to-severe HF                                                                 Kadokami *et al.*^[@bib64]^
                                                                                                                                                                                                                                                                                                      
  Necrosis    Cyclophilin D knockout                                                                           Transgenic mouse              Resistance to necrotic cell death induced by reactive oxygen species and Ca^2+^ overload and a high level of resistance to I/R-induced cardiac injury   Baines *et al.*^[@bib73]^; Nakagawa *et al.*^[@bib74]^
              Acute treatment with cyclosporin A, a MPTP inhibitor, during percutaneous coronary angioplasty   Clinical trials               Reduction of infarct size and reduced creatine kinase and troponin I release                                                                            Piot *et al.*^[@bib75]^
              Necrostatin-1                                                                                    Mouse                         Reduction of infarct size after I/R                                                                                                                     Lim *et al.*^[@bib76]^

Abbreviations: HF, heart failure; I/R, ischemia/reperfusion; MI, myocardial infarct

###### Patent applications related to autophagy, apoptosis, and necrosis for the treatment of cardiovascular diseases

  **Type**                 **Patent category**                          **Therapeutic/Target**                                                                                   **Remarks**                                                                    **Patent number**
  ------------------------ -------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------
  Necrosis                 Necrosis inhibitor                           4-(4-Chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2 h)-phthalazinone                            MIS                                                                            JP63218622
                           Necrosis inhibitor                           Potassium channel activator, such as pinacidil or cromakalim                                             I/R                                                                            EP0351767
                           Necrosis inhibitor                           1,4-Benzoxazine derivative such as Na^+^/H^+^ exchange inhibitor                                         MIS, cardiac dysfunction, myocardial necrosis, arrhythmia, RI, MI              US5597820
                           Necrosis inhibitor                           Benzo\[1,4\]thiazine derivatives such as Na^+^/H^+^ exchange system inhibitor                            MIS, MI, angina pectoris                                                       WO9813357
                           Necrosis inhibitor                           Benzothiophen-2-carbonylguanidine derivatives                                                            I/R                                                                            US2010004466
                                                                                                                                                                                                                                                                 
  Necrosis and apoptosis   TNF-*α* inhibitor/antagonist                 Human recombinant antibodies anti TNF-*α*                                                                MIS                                                                            WO9729131
                           TNF-*α* inhibitor/antagonist                 Soluble TNF receptor                                                                                     HF                                                                             WO0059530
                           TNF-*α* inhibitor/antagonist                 Inhibition of TNF-*α* expression with adenosine                                                          CHF                                                                            US6221851
                           TNF-*α* inhibitor/antagonist                 Inhibition of TNF-*α* expression with phosphodiesterase type IV inhibitors                               CHF                                                                            EP0995439
                           TNF-*α* inhibitor/antagonist                 Soluble TNF-*α* receptor                                                                                 CHF                                                                            WO02080847
                           TNF-*α* inhibitor/antagonist                 Anti-TNF-*α* antibodies                                                                                  Heart pathologies underlying excess TNF-*α*                                    US2003180299
                           TNF-*α* inhibitor/antagonist                 Anti-TNFR1 polypeptides based on antibody single-variable domains                                        Heart necrosis                                                                 WO2010081787
                           TNF-*α* inhibitor/antagonist                 Bicyclosulfonyl acid compounds                                                                           CHF, I/R                                                                       US2010311741
                           FAS inhibitor/antagonist                     Antibody against human FAS                                                                               MI, MIS, I/R                                                                   US2010233157
                           PARP inhibitor                               3,6-Substituted 5-arylamino-1H-pyridine-2-one derivatives                                                MIS, diabetic myocardial disease                                               US2007281948
                           PARP inhibitor                               Truncated PPAR inhibitor                                                                                 HF                                                                             WO2009043953
                                                                                                                                                                                                                                                                 
  Apoptosis                Caspase inhibitor                            Nicotinyl aspartyl ketones derivatives such as caspase-3-inhibiting compounds                            I/R                                                                            WO0127085
                           Caspase inhibitor                            Isoxazoline derivatives                                                                                  MIS                                                                            US6747050
                           Caspase inhibitor                            Substituted *α*-hydroxy acid such as potent inhibitors of caspases and apoptotic cell death              MI, I/R, CHF, C                                                                WO0116093
                           Caspase inhibitor                            Protein inhibitor of caspase 3                                                                           MIS, conduction disturbance, chronic heart diseases                            JP2002355077
                           Caspase inhibitor                            Inhibitor of caspase 3 or caspase-activated desoxyribonuclease inhibitor                                 HF                                                                             US2003130216
                           Caspase inhibitor                            2-Aminobenzamide derivatives                                                                             MI, CHF, C                                                                     US2003181388
                           Caspase inhibitor                            Dipeptide derivatives                                                                                    MI, CHF, C                                                                     US2003181391
                           Caspase inhibitor                            Dipeptide derivatives                                                                                    MI, CHF, HF, C                                                                 US2004116355
                           Caspase inhibitor                            Substituted piperidine, tetrahydroquinoline, or tetrahydroisoquinoline                                   MIS, MI, CHF, ATH, coronary artery bypass graft                                WO0190070
                           Caspase inhibitor                            Antisense for MIAP1, MIAP2, MIAP3, CIAP1, CIAP2, XIAP, APAF1, RAIDD, and Diablo/SMAC                     Cardiac disorders                                                              US2004254136
                           Caspase inhibitor                            Cell wall of *Chlorella pyrenoidosa*                                                                     MIS                                                                            JP2005089324
                           Caspase inhibitor                            Pyridazinone derivatives                                                                                 MIS                                                                            WO2008016239
                           Caspase inhibitor                            Danshensu derivatives                                                                                    MIS                                                                            CN101607904
                           Caspase inhibitor                            Peptide derivatives                                                                                      MIS                                                                            US2010184703
                           Caspase inhibitor                            Inhibition of OMI/HTRA2                                                                                  HF, MI                                                                         US2010311772
                           Caspase inhibitor                            Isoxazoline derivative                                                                                   MIS                                                                            WO2006090997
                           Intervention of Bcl2-related proteins        Modified Bcl-xL                                                                                          MI, I/R                                                                        WO2004110471
                           Intervention of Bcl2-related proteins        Antisense oligonucleotide against BNIP3                                                                  Hypoxia-acidosis-associated cardiac cell death                                 WO2004009780
                           Apoptosis inhibitor                          2-Substituted-4H-1,3-benzothiazine-4-one compounds                                                       Heart diseases                                                                 US2003186971
                           Apoptosis inhibitor                          Extracts of *Radix salviae miltiorrhizae* and *Rhizoma cnidii*                                           To inhibit apoptotic cardiac cell death                                        KR20040000651
                           Apoptosis inhibitor                          3-\[4-(4-Chlorophenyl)piperazin-1-yl\]methyl-1H-pyrrolo\[2,3-b\]pyridine                                 MIS, C                                                                         EP1815866
                           Apoptosis inhibitor                          Human FAF1 protein inhibitor                                                                             MIS, HF, diabetic CVD, H                                                       KR100818752
                           Apoptosis inhibitor                          Aminothiophene derivatives                                                                               MIS, diabetic CVD, HF, H                                                       WO2008140214
                           Apoptosis inhibitor                          Recombinant human ARC protein                                                                            C, MI, HF                                                                      CN101307320
                           Apoptosis inhibitor                          1,3-Benzothiazinone                                                                                      Heart disease                                                                  US2009082343
                           Apoptosis inhibitor                          Tetrahydroisoquinolines                                                                                  MI, MIS                                                                        US2009306130
                           Apoptosis inhibitor                          Deletion or silencing of midkine                                                                         I/R                                                                            US2010056437
                           Apoptosis inhibitor                          Extracts of Gramineae plant                                                                              MIS                                                                            US2010068315
                           Apoptosis inhibitor                          Corynantheine, the alkaloid extract from Uncaria                                                         MIS                                                                            WO2010043109
                                                                                                                                                                                                                                                                 
  Autophagy                Autophagy induction                          8-Methylchroman-7-ol derivatives                                                                         ATH, MIS                                                                       US2010173983
                           Proteinopathy treatment                      Farnesyl transferase inhibitor                                                                           MI, MIS, vascular hyperplasia, H, CHF, restenosis, ATH, HT, angina pectoris,   US2010160372
                           Autophagy regulation                         Cell permeable Tat-Atg5K130R (inhibitor of autophagy) and Tat-Beclin l (activator of autophagy)          HF, I/R                                                                        WO 2011106684
                           Autophagy regulation                         Compounds that regulates ATG14L and rubicon, which binds class III PI3K/Vps34--Beclin 1 complex          Inflammatory cardiac diseases                                                  WO2010030936
                           Autophagy induction                          Glycosylated anti-tumor ether lipids are small molecules that induce and/or enhance autophagy in cells   I/R                                                                            WO2009092170
                           Autophagy regulation                         Autophagy modulators identified by a high-throughput phenotypic screen                                   MIS, I/R                                                                       WO2008122038
                           Cardiac autophagy death regulation           siRNA against ANT isoforms, which selectively regulates autophagic cell death                            MIS                                                                            US20060210535
                           Autophagy regulation                         A phosphorus-rapamycin analog, AP23573                                                                   Restenosis, ATH, CVD, cerebral vascular disease, peripheral vascular disease   US20040073024
                           Anti-cardiac autophagic degeneration/death   Long-term administration of a colony-stimulating factor (G-CSF)                                          MIS, F, LVR                                                                    US2006051318
                           Cardiac atrophy                              Agent that increases the expression of the *runx1* gene to prevent or decrease cardiac autophagy         Treatment of a heart condition whereby heart muscle is destroyed               US2006003959

Abbreviations: ATH, atherosclerosis; C, cardiomyopathy; CHF, congestive heart failure; CVD, cardiovascular disease; F, myocardial fibrosis; HF, heart failure; HT, hypertension; I/R, ischemia/reperfusion; LVR, left ventricular remodeling; MI, myocardial infarction; MIS, myocardial ischemia; RI, reperfusion injury
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